Zydus Lifesciences Limited — PPTs, 11-08-2026: Investor Presentation

Zydus Lifesciences reported Q1 FY27 results with total revenue up 22% YoY to ₹8,017 Cr. Profit after tax (PAT) however, saw a 35.9% YoY dip to ₹939.8 Cr, and EBITDA fell 7.6% YoY to ₹1,929.4 Cr. #Pharma #Earnings

India Formulations shined with ~20% YoY growth. International Markets also surged ~34% YoY, and Consumer Wellness saw robust ~67% YoY growth. North America Formulations showed sequential growth but a slight YoY decline. #ZydusLife

Strategic moves include expanding the US specialty portfolio with the Assertio Holdings acquisition & launching NUFYMCO, their first biosimilar in the US. They also received USFDA priority review for Saroglitazar for PBC. #Innovation #Expansion

Company continues investing in its R&D pipeline (R&D at ₹642.4 Cr) for new drugs and vaccines. Net Debt stands at ₹5,904.1 Cr. #RetailInvestor #Healthcare